Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)
An Open-Label, Multicenter, Historically-Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Acute Liver Failure (ALF)
Sponsor: Vital Therapies, Inc.
Terminated
Due to VTI-208 results, the ELAD clinical plan is being re-evaluated.
Other terminated trials from Vital Therapies, Inc.
- Severe Acute Alcoholic Hepatitis · Phase PHASE3 · Sep 2018
- Acute Alcoholic Hepatitis · Phase PHASE3 · Sep 2018
More terminations from Vital Therapies, Inc.
Other Acute Liver Failure trials with similar outcome
A PHASE2 clinical study on Acute Liver Failure and Fulminant Hepatic Failure, this trial is terminated or withdrawn. The trial is conducted by Vital Therapies, Inc. and has accumulated 13 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 8 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Terminated PHASE2
-
Sep 2018 — Feb 2019 [monthly]
Terminated PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vital Therapies, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .